No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...